WHITEHAWK THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $13.45 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-07.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2019-03-07
- WHITEHAWK THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2017-12-31 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2017-09-30 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2017-06-30 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2017-03-31 was $13.45M.
- WHITEHAWK THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2017 was $13.45M, a 16137.94% increase from fiscal 2016.
- WHITEHAWK THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2016 was $82.82K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 derived: sum of 3 quarters · filed 2019-03-07 | $13.45M 10-K · filed 2019-03-07 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $0.00 derived: sum of 2 quarters · filed 2017-11-13 | $13.45M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $13.45M 10-Q · filed 2017-08-10 | ||
| 2017-03-31 | $13.45M 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | $82.82K 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |